ADC Therapeutics (ADCT) Receivables (2021 - 2026)

ADC Therapeutics (ADCT) has reported Receivables for 6 consecutive years, with $31.0 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables fell 2.26% year-over-year to $31.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.0 million (down 2.26% YoY) and the FY2025 annual result came in at $29.1 million, up 43.32% from the prior year.
• Receivables improved to $31.0 million in Q1 2026 per ADCT's latest filing, from $29.1 million in the prior quarter.
• Over the last five years, Receivables for ADCT reached as high as $73.8 million in Q4 2022 and fell as low as $20.3 million in Q4 2024.
• A 5-year average of $28.2 million and a median of $25.1 million in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 945.65% — and 2023, when it tumbled 65.87%.
• Year by year, Receivables stood at $73.8 million in 2022, then plunged by 65.87% to $25.2 million in 2023, then slipped by 19.32% to $20.3 million in 2024, then jumped by 43.32% to $29.1 million in 2025, then gained by 6.62% to $31.0 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $31.0 million, $29.1 million, and $22.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.